Alphyn Biologics Reports Interim Results from P-IIa Clinical Trial of AB-101a for Atopic Dermatitis with Secondary Bacterial Infection
Shots:
- The interim results from the second cohort of the P-IIa trial program evaluating AB-101a. The results showed AB-101a meets all EPs for safety & efficacy, 80% of patients achieved an itch score improvement of ≥4, 90% & 44% had an EASI score improvement of 50% & 75%
- 40% reduction of disease severity indicated by ≥2 improvements in IGA score, 64% achieved clear or almost clear, infections cleared (100%), SIRS score improvement of 6 or more points (82%) equal to an improvement of 55-75%
- Patients showed a steady decrease in SIRS score which demonstrates control of the AD skin bacterial microbiome & control of the AD flares caused by bacteria. The company plans to initiate a P-IIb trial with sites in the US, EU, Canada & Australia
Ref: PR Newswire | Image: Alphyn Biologics
Related News:- Incyte Reports P-III Study (TRuE-AD3) Results of Opzelura (ruxolitinib) for Children with Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
